WO1994018178A1 - Process for preparing tetrazole-5-carboxylic acid derivatives - Google Patents
Process for preparing tetrazole-5-carboxylic acid derivatives Download PDFInfo
- Publication number
- WO1994018178A1 WO1994018178A1 PCT/EP1994/000305 EP9400305W WO9418178A1 WO 1994018178 A1 WO1994018178 A1 WO 1994018178A1 EP 9400305 W EP9400305 W EP 9400305W WO 9418178 A1 WO9418178 A1 WO 9418178A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- sodium
- optionally substituted
- tetrazole
- ethyl
- Prior art date
Links
- 0 C=*(C(c(cc1)ccc1O)=O)c(cccc12)c1OC(C1=**=**1=C)=CC2=C Chemical compound C=*(C(c(cc1)ccc1O)=O)c(cccc12)c1OC(C1=**=**1=C)=CC2=C 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D257/04—Five-membered rings
Definitions
- the present invention relates to a novel process for preparing certain tetrazole compounds which are of use in the preparation of therapeutically active substances, in particular certain benzopyran compounds useful as inhibitors of 5- ⁇ -reductase and as leukotriene antagonists.
- the invention further relates to novel salt forms of the tetrazole compounds and to a process for preparing them.
- R! is, inter alia, or a carboxylic group
- X is oxygen or sulphur
- R ⁇ and R-- * are, for example, hydrogen, by cyclisation of the corresponding intermediate compounds of structure (B):
- the tetrazole compounds (D) and the salts thereof can be prepared in high yield and in high purity, avoiding the undesirable azide by-products associated with known methods.
- the present invention therefore produces, in a first aspect, a process for preparing a compound of structure (I):
- R ⁇ is Cj.galkyl, optionally substituted phenyl or optionally substituted phenylCj.galkyl
- R 1 is C- ⁇ alkyl . for example, methyl, ethyl, i-butyl or t-butyl.
- alkali metal atoms M include lithium, sodium and potassium.
- M is sodium or potassium.
- the reaction between the compounds of structures (II) and (III) is carried out in a suitable solvent in the presence of an acid, at a temperature of between ambient and reflux temperature of the solvent used, for as long as is required to take the reaction to completion.
- suitable solvents include 2,6-lutidine and suitable acids include trifluoroacetic acid.
- the salts (IV) readily precipitate out from the mixture, leaving behind undesirable hazardous by-products (and any unreacted starting materials which may be re-used in subsequent reactions) and can then be converted to the high purity tetrazoles (I).
- the conversion of the salts (TV) to the tetrazoles (I) can be accomplished, for example, by treatment with an acid, such as dilute HC1 as described hereinafter in the Examples.
- the preparation of tetrazoles of structure (I) via the salts (IV) is a very efficient process and provides a broad general process for the preparation of salts of tetrazoles of structure (I) by providing a convenient, safe and efficient preparation of the 'free' tetrazoles of structure (I).
- the present invention therefore provides in a further aspect a process for preparing a compound of structure (V):
- Suitable and preferred groups R are as described for structure (I).
- Suitable ions X include, for example, alkali metal ions such as lithium, sodium or potassium; group II
- ion + ions such as calcium and magnesium
- Other groups X will be apparent to those skilled in the art. Suitable compounds providing the source of ion X will be apparent to those skilled in the art, and include, for example, alkali metal alkoxides such as sodium methoxide, and soluble ion alkanoate salts such as salts of alkyl-2-hexanoic acids, in particular sodium or potassium ethyl hexanoate as hereinafter described.
- Alternative ion sources include, for example, alkali metal halides such as sodium iodide, alkali metal acetates such as sodium trifluoroacetate, and ion exchange resins loaded with the ion X as appropriate.
- the salts (V) can not only be prepared from the free tetrazoles (I) but can also be prepared by conversion from a different salt (V), for example via anion exchange using a suitable anion exchange resin.
- the source of ion X can, in practice, also be a compound of structure (V) itself.
- salts of structure (I) can be isolated in solid form and as such are very stable and can be readily transported in pure form.
- R 1 is C ⁇ alkyl, optionally substituted phenyl or optionally substituted phenylCj. ⁇ alkyl
- X is an ion, characterised in that the compound (V) is in solid form. Suitable values of R and X are as described above.
- 2,6-Lutidine (115ml) was stirred under nitrogen and trifluoroacetic acid (20.5ml) added cautiously over 15 minutes, maintaining the temperature at +5 to +10°C by cooling in an ice bath.
- Powdered sodium azide (17.8g) was added, followed by ethyl cyanoformate (24.8g) and the reaction mixture heated slowly to ca. 80°C.
- the mixture was stirred at 75 to 80°C for 5.5 hours, allowed to cool to room temperature and filtered.
- the white crystals were washed with ethyl acetate (3 x 50ml) and dried in vacuo to constant weight.
- the intermediate sodium salt (equivalent to 33g of pure material), prepared as described in Example 2 (a), was suspended in a mixture of saturated brine (100ml) and ethyl acetate (100ml), and sodium nitrite (5.2g) added. The mixture was cooled to ca. 10°C and cautiously treated with concentrated hydrochloric acid (60ml) with ice cooling. Further sodium chloride was added to saturate the aqueous phase.
- the phases were separated and the aqueous phase further extracted with ethyl acetate (2 x 50ml).
- the combined ethyl acetate phases were evaporated on a rotary evaporator to about 65g and treated with toluene (65g).
- the mixture was again evaporated to about 65g to give a suspension of the product as a crystalline solid. This was collected by filtration, washed with toluene and dried.
- 2,6-Lutidine (115ml) was stirred under nitrogen and cooled in an ice bath. Trifluoroacetic acid (20.5ml) was added cautiously over 15 minutes, maintaining the temperature at +5 to +12°C, followed by sodium azide (17.8g) and the mixture stirred well. Ethyl cyanoformat (24.8g) was then added over about 2 minutes and the reaction mixture heated slowly to ca. 80°C. The mixture was stirred at 75 to 80°C for 3.5 hours, allowed to cool to room temperature and filtered. The white crystals were washed with ethyl acetate (4 x 20ml) and dried in vacuo.
- the sodium salt prepared in a) contained a trace of unreacted sodium azide and small amounts of other impurities. These were removed and the material converted to the potassium salt as follows:
- the intermediate sodium salt (14g) was dissolved in ice-cold water (50ml) and treated with sodium nitrite (1.5g). A mixture of cone, hydrochloric acid (15ml) and water (35ml) was then added slowly, keeping the temperature below 5°C. The mixture was stirred for 15 minutes, then treated with urea (1.6g) to destroy the excess nitrous acid. When gas evolution had subsided the solution was saturated with sodium chloride (30g) and extracted with ethyl acetate (100ml).
- the aqueous phase was further extracted with ethyl acetate (2 x 50ml) and the combined ethyl acetate extracts washed with saturated brine (50ml) and dried by stirring with magnesium sulphate (30g) for 30 minutes.
- 2,6-Lutidine 100ml was stirred under nitrogen, and cooled in an ice-bath.
- Trifluoroacetic acid (5.0ml) was added cautiously over 15 minutes, maintaining the temperature at +5 to +12°C, followed by sodium azide (17.8g) and the mixture stirred well for 15 minutes.
- Ethyl cyanoformate ( 24.8g) was then added over about 3 minutes and the reaction mixture heated slowly to ca. 80°C. After an initial exotherm in which the temperature reached 94°C, the mixture was stirred at 80°C for 4.0 hours, cooled to room 10°C and filtered.
- the sodium salt (30g) and sodium nitrite (1.75g) were dissolved in water ( 75ml), covered with ethyl acetate (100ml) and cooled 10°C. 2M hydrochloric acid (120ml) was then added slowly with stirring, and the mixture stirred for 30 minutes, allowing the temperature to rise to 20°C.
- the phases were separated, the aqueous phase saturated with sodium chloride and further extracted with ethyl acetate (3 x 50ml).
- the combined ethyl acetate phases were treated slowly with a solution of sodium- 2-ethyl hexanoate (31.0g) in ethyl acetate (100ml) to precipitate the product as fine needles.
- the infra-red spectrum was significantly different from that of the product of Example 1, and showed strong bands assigned to bound water at 3565 and 3935cm" 1 .
- Example 4 The hydrate from Example 4 was dried in vacuo, with a loss in weight of 17.7%. The product gave an infra-red spectrum indistinguishable from that of the product of Example
- Ethyl-5-tetrazole carboxylate (5.0g) was dissolved in ethyl acetate (40ml) and treated with a solution of sodium-2-ethyl hexanoate (6.5g) in ethyl acetate (15ml) over about 30 minutes with stirring at room temperature.
- the white suspension was diluted with ethyl acetate (50ml) and filtered.
- the product was washed on the filter with ethyl acetate and dried in vacuo over phosphorous pentoxide.
- Ethyl-5-tetrazole carboxylate (5.0g) was dissolved in ethyl acetate (150ml) and treated with a 2J6M solution of potassium-2-ethyl hexanoate in 2-propanol (20ml) over about 2 minutes with stirring at room temperature. The addition was interrupted briefly to allow the product to crystallise. The product was viewed under a polarising microscope and found to consist of rectangular prisms. These were collected by filtration, washed on the filter with ethyl acetate (25ml, 50ml) and dried in air.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP94906210A EP0682658A1 (en) | 1993-02-05 | 1994-02-01 | Process for preparing tetrazole-5-carboxylic acid derivatives |
US08/495,562 US5525733A (en) | 1993-02-05 | 1994-02-01 | Process for preparing tetrazole-5-carboxylic acid derivatives |
JP6517630A JPH08506332A (en) | 1993-02-05 | 1994-02-01 | Process for producing tetrazole-5-carboxylic acid derivative |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB939302331A GB9302331D0 (en) | 1993-02-05 | 1993-02-05 | Process |
GB9302331.5 | 1993-02-05 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1994018178A1 true WO1994018178A1 (en) | 1994-08-18 |
Family
ID=10729947
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP1994/000305 WO1994018178A1 (en) | 1993-02-05 | 1994-02-01 | Process for preparing tetrazole-5-carboxylic acid derivatives |
Country Status (5)
Country | Link |
---|---|
US (1) | US5525733A (en) |
EP (1) | EP0682658A1 (en) |
JP (1) | JPH08506332A (en) |
GB (1) | GB9302331D0 (en) |
WO (1) | WO1994018178A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111943899A (en) * | 2020-09-08 | 2020-11-17 | 河北凯力昂生物科技有限公司 | Synthesis method of 5-ethyl formate tetrazole |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5508272A (en) * | 1993-06-15 | 1996-04-16 | Bristol-Myers Squibb Company | Compounds containing a fused bicycle ring and processes therefor |
US6307090B1 (en) | 1999-01-22 | 2001-10-23 | The United States Of America As Represented By The Department Of Health And Human Services | Acylated oligopeptide derivatives having cell signal inhibiting activity |
US7226991B1 (en) * | 1999-03-23 | 2007-06-05 | United States Of America, Represented By The Secretary, Department Of Health And Human Services | Phenylalanine derivatives |
CA2855415A1 (en) * | 1999-03-23 | 2000-09-28 | The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Phenylalanine derivatives |
US7871981B2 (en) * | 1999-10-22 | 2011-01-18 | The United States Of America As Represented By The Department Of Health And Human Services | Inhibition of cell motility, angiogenesis, and metastasis |
ATE362767T1 (en) | 1999-10-22 | 2007-06-15 | Us Gov Health & Human Serv | INHIBITION OF CELL MOTILITY AND ANGIOGENESIS WITH GRB2 SH2-DOMAIN INHIBITORS |
US7425537B2 (en) * | 2000-08-22 | 2008-09-16 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | SH2 domain binding inhibitors |
EP1383792A2 (en) * | 2000-08-22 | 2004-01-28 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Sh2 domain binding inhibitors |
US20040138104A1 (en) * | 2003-01-14 | 2004-07-15 | The Government Of The United States Of America Represented By The Secretary, | Peptides |
US7223780B2 (en) * | 2003-05-19 | 2007-05-29 | Sanofi-Aventis Deutschland Gmbh | Triazole-derivatives as blood clotting enzyme factor Xa inhibitors |
US20050119163A1 (en) | 2003-09-18 | 2005-06-02 | The Government Of The United States Of America, As Represented By The Secretary, | SH2 domain binding inhibitors |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2407207A1 (en) * | 1977-10-28 | 1979-05-25 | May & Baker Ltd | NEW TETRAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
US4316037A (en) * | 1977-01-21 | 1982-02-16 | American Home Products Corporation | N-Benzyl and N-substituted benzyl tetrazole-5-carboxylic acids and the preparation thereof |
EP0323885A1 (en) * | 1988-01-05 | 1989-07-12 | May & Baker Limited | New chemical process |
-
1993
- 1993-02-05 GB GB939302331A patent/GB9302331D0/en active Pending
-
1994
- 1994-02-01 US US08/495,562 patent/US5525733A/en not_active Expired - Lifetime
- 1994-02-01 EP EP94906210A patent/EP0682658A1/en not_active Ceased
- 1994-02-01 WO PCT/EP1994/000305 patent/WO1994018178A1/en not_active Application Discontinuation
- 1994-02-01 JP JP6517630A patent/JPH08506332A/en not_active Ceased
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4316037A (en) * | 1977-01-21 | 1982-02-16 | American Home Products Corporation | N-Benzyl and N-substituted benzyl tetrazole-5-carboxylic acids and the preparation thereof |
FR2407207A1 (en) * | 1977-10-28 | 1979-05-25 | May & Baker Ltd | NEW TETRAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
EP0323885A1 (en) * | 1988-01-05 | 1989-07-12 | May & Baker Limited | New chemical process |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111943899A (en) * | 2020-09-08 | 2020-11-17 | 河北凯力昂生物科技有限公司 | Synthesis method of 5-ethyl formate tetrazole |
CN111943899B (en) * | 2020-09-08 | 2023-04-21 | 河北凯诺中星科技有限公司 | Synthesis method of 5-ethyl formate tetrazole |
Also Published As
Publication number | Publication date |
---|---|
GB9302331D0 (en) | 1993-03-24 |
US5525733A (en) | 1996-06-11 |
EP0682658A1 (en) | 1995-11-22 |
JPH08506332A (en) | 1996-07-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6124464A (en) | Process for the preparation of a magnesium salt of a substituted sulfinyl heterocycle | |
JP3421354B2 (en) | Crystalline cefdiniramine salt | |
EP0682658A1 (en) | Process for preparing tetrazole-5-carboxylic acid derivatives | |
WO2007053723A2 (en) | Process for the preparation of cefdinir | |
KR100403256B1 (en) | Crystalline N-Acetyl Neuraminic Acid Derivatives and Processes for Their Preparation | |
JP2002530376A (en) | New manufacturing method | |
SI21236A (en) | Process for the crystallization of losartan potassium | |
DE2512284A1 (en) | CEPHALOSPORANIC ACID DERIVATIVES, PROCESS FOR THEIR MANUFACTURING AND PHARMACEUTICAL PRODUCTS CONTAINING THEM | |
US4791210A (en) | Process for the production of 5-methyltetrazole | |
DE2655692A1 (en) | 3- (1-UREIDOALKYL) -TETRAZOLE-5-YLTHIOMETHYL-3-CEPHEM-4-CARBONIC ACID COMPOUNDS, METHOD FOR THEIR MANUFACTURING, MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS AND INTERMEDIATES | |
BG60439B2 (en) | Solid cephalosporinic salt | |
JPS5953277B2 (en) | Method for producing antibacterial agents | |
JP2936052B2 (en) | Purification of cephalosporin salt | |
US4140694A (en) | Intermediates for preparing 7-acyl-3-(sulfonic acid and sulfamoyl substituted tetrazolylthiomethyl)cephalosporins | |
JP2002504156A (en) | Synthetic process of carbapenem side chain intermediate | |
CA1122972A (en) | Cephalosporin compounds | |
JPS6254112B2 (en) | ||
JP2001278867A (en) | Method for producing cyclic acid | |
CA2268775C (en) | Process for the preparation of phtalide | |
AU2001288535A1 (en) | Crystalline forms of carbapenem intermediates | |
JP3834184B2 (en) | Condensing agent and storage method thereof | |
JP4587529B2 (en) | Method for producing ipidacrine and ipidacrine hydrochloride hydrate | |
JP4689803B2 (en) | Process for producing (2S, 4S) -N, N-dimethyl-1-allyloxycarbonyl-4-benzoylthio-2-pyrrolidinecarboxamide | |
KR830000376B1 (en) | Process for preparing cephalosporin compound | |
KR960011779B1 (en) | Novel process for preparing crystalline hydrate of cephalosporin |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): JP US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1994906210 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 08495562 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 1994906210 Country of ref document: EP |
|
WWR | Wipo information: refused in national office |
Ref document number: 1994906210 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1994906210 Country of ref document: EP |